Sponsored Links 
Amylin's Bad Byetta News
In a note received just now from Zacks senior biotechnology analyst Jason Napodano, CFA, the Food & Drug Administration [FDA] just issued a warning on Amylin's (AMLN - Analyst Report) diabetes drug, Byetta, on a potential risk for pancreatitis.
According to the report, there have been six reported cases, with two deaths in a recent-enough time frame that the FDA believes warnings doctors and patients is necessary. The stock is already down 10% on the news.
From the analyst: "We have a SELL on Amylin and continue to recommend investors avoid the name."
Read the full analyst report on AMLN
 |
 |
 Share |
 RSS |
 Rate Pos |
 Rate Neg |
 Comment |
|
|
||||||
Free Stock Analysis From Zacks
Includes Zacks Long-Term Recommendation and Target Price
Loading Stories...Related Content
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Zacks FREE Registration
X Close
Loading Stories...Most Popular on Zacks.com
0.58 %
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Feb 09, 2010 22:03 pm ET |
[CLICK TO CLOSE X]